Yüklüyor......
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
PURPOSE: We aimed to assess the patient-reported outcome (PRO) and efficacy of add-on low-dose antimuscarinic therapy in over-active bladder (OAB) patients with suboptimal response to 4-week treatment with beta 3 agonist monotherapy (mirabegron, 50 mg). MATERIALS AND METHODS: We enrolled OAB patient...
Kaydedildi:
| Yayımlandı: | Investig Clin Urol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The Korean Urological Association
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5494350/ https://ncbi.nlm.nih.gov/pubmed/28681036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.2017.58.4.261 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|